Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy



Summary

Nanobody-based bispecific antibody engagers offer a promising avenue for cancer immunotherapy. These molecules combine the target specificity of nanobodies, small and stable antibody fragments, with the ability to simultaneously engage immune cells and tumor cells. By targeting immune checkpoint molecules like CTLA-4 or PD-L1 on tumor cells or immune cells, these bispecifics can disrupt immunosuppressive signaling pathways, activating T cells to effectively kill cancer cells. This approach allows for targeted immune activation at the tumor microenvironment, potentially minimizing systemic toxicity and improving therapeutic efficacy compared to traditional antibody therapies.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!